Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Part of paid clinical trials in Rochester, New York.

Sponsor
Aram Hezel
Study ID
NCT06203821
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NP137 — DRUG
    NP137 for the Treatment of Resectable Pancreatic Cancer

Study Details

The objective of this study is to investigate whether adding the study drug, NP137, to a patient's treatment regimen (before surgery and in combination with chemotherapy afterward) can alter the behavior of pancreatic cancer..

Key Dates

Start date
Sep 1, 2026
Status verified
Mar 2025
Primary completion
May 30, 2027
Completion
Sep 30, 2032

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Patient receive two doses of the study drug, NP137, approximately two weeks apart. This will be followed by surgery. After the surgery if feasible, patients will begin post-surgical treatment with a standard-of-care chemotherapy regimen called FOLFIRINOX, combined with the study drug, NP137, for a total duration of about 6 months. Upon completing this phase, patients will receive an additional 6 months of treatment with only the study drug NP137.

Primary Outcome Measure

Determining if NP137 can shift the primary tumor MAK's Signature Epithelial-to-Mesenchymal Transition (EMT) Mean Score towards a more epithelial phenotype [ Time Frame: 3-5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of RochesterRochesterNew York14642
Aram Hezel
[email protected]
585-275-5863
Aram Hezel (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, NY

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
University of Rochester· Rochester, NY

Related Studies